80 Results

People

  1. Riely
    Riely
  2. Kris
    Kris
  3. Miller
    Miller
  4. Pao
    Pao
  5. Ladanyi
    Ladanyi
  6. Rizvi
    Rizvi
  7. Rusch
    Rusch
  8. Rudin
    Rudin
  9. Sima
    Sima
  10. Azzoli
    Azzoli

Groups

  1. Department of Medicine (80)
  2. Solid Tumor Oncology Division (80)
  3. Thoracic Oncology (80)
  4. GSK Faculty (31)
  5. Human Oncology and Pathogenesis Program (29)
  6. Tow Center for Developmental Oncology (TCDO) (25)
  7. Epidemiology and Biostatistics (16)
  8. Biostatistics Service (14)
  9. Radiology, Department of (14)
  10. Sloan Kettering Institute Postdocs (13)
  1. "lung neoplasms"
  2. "Gregory Riely"
Formats
  1. Journal Article (71)
  2. Guidelines (5)
  3. Review (2)
  4. Conference Paper (1)
  5. Editorial (1)
Groups
  1. Department of Medicine (80)
  2. Solid Tumor Oncology Division (80)
  3. Thoracic Oncology (80)
  4. GSK Faculty (31)
  5. Human Oncology and Pathogenesis Program (29)
  6. Tow Center for Developmental Oncology (TCDO) (25)

More Groups

People
  1. Gregory Riely (80)
  2. Mark Kris (33)
  3. Marc Ladanyi (24)
  4. Vincent Miller (22)
  5. William Pao (16)
  6. Maria Arcila (9)

More People

Years
  1. 2024 (2)
  2. 2023 (15)
  3. 2022 (9)
  4. 2019 (2)
  5. 2018 (1)
  6. 2017 (3)

More Years

Publications
  1. Clinical Cancer Research (21)
  2. Journal of Clinical Oncology (8)
  3. Journal of Thoracic Oncology (8)
  4. Journal of the National Comprehensive Cancer Network (6)
  5. Cancer (5)
  6. JAMA - Journal of the American Medical Association (2)

More Publications

Publishers
  1. American Association for Cancer Research (25)
  2. American Society of Clinical Oncology (9)
  3. Elsevier Inc. (9)
  4. Harborside Press (6)
  5. Wiley Blackwell (5)
  6. Elsevier Science, Inc. (3)

More Publishers

Results (80)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFT bypass signaling
    Journal Article

    Chen, N.; Tyler, L. C.; Le, A. T.; Welsh, E. A.; Fang, B.; Elliott, A.; Davies, K. D.; Danhorn, T.; Riely, G. J.; Ladanyi, M.; more...
    Molecular Cancer Therapeutics (2024)

    Fulltext@MSK | Save
  • Effects of KRAS genetic interactions on outcomes in cancers of the lung, pancreas, and colorectum
    Journal Article

    Grabski, I. N.; Heymach, J. V.; Kehl, K. L.; Kopetz, S.; Lau, K. S.; Riely, G. J.; Schrag, D.; Yaeger, R.; Irizarry, R. A.; Haigis, K. M.
    Cancer Epidemiology Biomarkers and Prevention (2024)

    Fulltext@MSK | Save
  • Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer
    Journal Article

    Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer
    Journal Article

    Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Rizvi, H.; Elkrief, A.; Luo, J.; Alessi, J. V.; Pecci, F.; Lamberti, G.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • The GENIE BPC NSCLC cohort: A real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
    Journal Article

    Choudhury, N. J.; Lavery, J. A.; Brown, S.; de Bruijn, I.; Jee, J.; Tran, T. N.; Rizvi, H.; Arbour, K. C.; Whiting, K.; Shen, R.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO Living Guideline, version 2023.2
    Guidelines

    Owen, D. H.; Singh, N.; Ismaila, N.; Masters, G.; Riely, G. J.; Robinson, A. G.; Schneider, B. J.; Jaiyesimi, I. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
    Journal Article

    Elkrief, A.; Alessi, J. M. V.; Ricciuti, B.; Brown, S.; Rizvi, H.; Preeshagul, I. R.; Wang, X.; Pecci, F.; Di Federico, A.; Lamberti, G.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Early changes in circulating cell-free KRAS G12C predict response to adagrasib in KRAS mutant non-small cell lung cancer patients
    Journal Article

    Paweletz, C. P.; Heavey, G. A.; Kuang, Y.; Durlacher, E.; Kheoh, T.; Chao, R. C.; Spira, A. I.; Leventakos, K.; Johnson, M. L.; Ou, S. H. I.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer
    Journal Article

    Riely, G. J.; Smit, E. F.; Ahn, M. J.; Felip, E.; Ramalingam, S. S.; Tsao, A.; Johnson, M.; Gelsomino, F.; Esper, R.; Nadal, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save